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This is one of a series of BMJ summaries of new guidelines, which are
based on the best available evidence; they highlight important
recommendations for clinical practice, especially where uncertainty or
controversy exists.
Why read this summary?
Rheumatoid arthritis is a chronic, progressive autoimmune
disease associated with inflammation principally in synovial
joints and affecting over 400 000 people in the United
Kingdom.
1 In recent years it has become clear that pain and
disability can be avoided if the disease is recognised early and
treated promptly and appropriately. It is therefore crucial that
all health professionals have knowledge of the recognition,
management, and appropriate referral of patients with
rheumatoid arthritis. This article summarises the
recommendations in the guideline from the National Institute
for Health and Clinical Excellence (NICE) on the management
of rheumatoid arthritis, from early identification to managing
chronic and severe disease.
2
Recommendations
NICErecommendationsarebasedonsystematicreviewsofbest
available evidence. When minimal evidence is available,
recommendations are based on the opinion of the Guideline
Development Group (GDG) of what constitutes good practice.
Evidence levels for the recommendations are given in italic in
square brackets.
Referral, diagnosis, and investigations
• Refer for specialist opinion anyone with suspected
persistent synovitis of undetermined cause. Refer urgently
even if blood tests show a normal acute-phase response or
negative rheumatoid factor and if:
-The small joints of the hands or feet are affected
-More than one joint is affected, or
-There has been a delay of three months or longer between
symptom onset and seeking medical advice.
[Based on high and moderate quality observational studies of
early prognosis and identification or diagnosis]
• Offertotestforrheumatoidfactorinpeoplewithsuspected
rheumatoid arthritis who have synovitis. [Based on high
and moderate quality early identification observational
studies]
• Consider measuring anticyclic citrullinated peptide
antibodies in people with suspected rheumatoid arthritis
if:
-They are negative for rheumatoid factor, and
-Combination therapy is being considered (see section on
disease modifying antirheumatic drugs).
[Based on data from case series]
• X ray the hands and feet early in people with persistent
synovitis in these joints.[Based on high and moderate
quality early identification studies]
Communication and education
• Offer verbal and written information to people with
rheumatoid arthritis to:
-Improve their understanding of the condition and its
management, and
-Counter any misconceptions they may have.
• For those wishing to know more, offer participation in
existing educational activities, including self management
programmes.
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Practice
PRACTICE[Bothrecommendationsarebasedonhighandmoderatequality
meta-analyses, randomised controlled trials, and the GDG’s
opinion]
The multidisciplinary team
• Ensure ongoing access to a multidisciplinary team with
opportunity for periodic assessments and help to manage
the condition. [Based on moderate quality randomised
controlled trials, case series, and the GDG’s opinion]
• Ensure people with rheumatoid arthritis have access to a
namedmemberofthemultidisciplinaryteam(forexample,
the specialist nurse), who is responsible for coordinating
their care. [Based on moderate quality randomised
controlled trials, case series, and the GDG’s opinion]
• Ensure access, with periodic review, to:
-Specialist physiotherapy to enhance general fitness, joint
flexibility, and muscle strength; to improve function; and
to learn about short term pain relief provided by methods
suchastranscutaneouselectricalnervestimulators(TENS)
and wax baths.
-Specialistoccupationaltherapyiftheyhaveproblemswith
everyday activities or hand function.
-A podiatrist if they have foot problems, and make sure
functional insoles and therapeutic footwear are available
if indicated.
[Based on high quality meta-analyses and high and moderate
quality randomised controlled trials, and the GDG’s opinion]
• Offerpsychologicalinterventions(forexample,relaxation,
stress management, and cognitive coping skills) to help
adjust to living with the condition. [Based on high quality
meta-analyses and high and moderate quality randomised
controlled trials]
Management of symptoms: analgesics and
NSAIDs
Analgesics
• Offer analgesics (for example, paracetamol, codeine, or
compound analgesics) if pain control is inadequate, to
potentially reduce their need for long term treatment with
non-steroidal anti-inflammatory drugs (NSAIDs) or
cyclo-oxygenase-2(COX2)inhibitors.[Basedonmoderate
quality randomised controlled trials, case series, and the
GDG’s opinion]
Non-steroidal anti-inflammatory drugs
• WhenofferinganoralNSAIDorCOX2inhibitor,thefirst
choice should be either a standard NSAID or a COX 2
inhibitor (other than etoricoxib 60 mg) at the lowest
effectivedosefortheshortestpossibletime.Ineithercase,
coprescribe a proton pump inhibitor with the lowest
acquisition cost.
• All oral NSAIDs and COX 2 inhibitors have analgesic
effects of a similar magnitude but vary in their potential
gastrointestinal, liver, and cardiorenal toxicity; therefore,
whenchoosingtheagentanddose,considertheindividual’s
risk factors, including age. When prescribing these drugs,
considerappropriateassessmentand/ormonitoringofthese
risk factors.
• Ifapersonwithrheumatoidarthritisneedstotakelowdose
aspirin, consider other analgesics before substituting or
addinganNSAIDorCOX2inhibitor(withaprotonpump
inhibitor) if pain relief is ineffective or insufficient.
• If NSAIDs or COX 2 inhibitors are not providing
satisfactory symptom control, review the regimen for
disease modifying or biological drugs.
[The above four NSAID recommendations are based on
randomised controlled trials (mostly moderate quality), case
series, and the GDG’s opinion]
Managementofsymptoms:diseasemodifying
antirheumatic drugs
For people with newly diagnosed active disease
• Offer a combination of disease modifying antirheumatic
drugs as first line treatment as soon as possible, ideally
within three months of the onset of persistent symptoms.
This should include methotrexate and at least one other,
plus short term glucocorticoids. [Based on high and
moderatequalitymeta-analysesandrandomisedcontrolled
trials, moderate quality cohort studies, health economic
modelling, and the GDG’s opinion]
• If combination therapy with disease modifying drugs is
not appropriate (for example, owing to comorbidities or
pregnancy),startmonotherapy,focusingonfastescalation
to a clinically effective dose rather than choice of drug.
[Based on high and moderate quality meta-analyses and
randomised controlled trials, moderate quality cohort
studies, health economic modelling, and the GDG’s
opinion]
• Offer short term oral, intramuscular, or intra-articular
glucocorticoids to rapidly improve symptoms (if the
individual is not already receiving glucocorticoids as part
ofthecombinationtherapy).[Basedonhighandmoderate
quality randomised controlled trials and the GDG’s
opinion]
For people with recent onset disease (within past
two years)
• If they have achieved sustained and satisfactory levels of
disease control with a combination of disease modifying
antirheumaticdrugs,cautiouslytrytoreducedosestolevels
that still maintain disease control. [Based on high and
moderatequalitymeta-analysesandrandomisedcontrolled
trials, moderate quality cohort studies, and the GDG’s
opinion]
For people with established disease (longer than
two years)
• If disease is stable, cautiously reduce dosages of disease
modifying or biological drugs; return promptly to disease
controlling doses at the first sign of a flare-up.
• When introducing new drugs to improve disease control,
considerdecreasingorstoppinganindividual’spre-existing
rheumatological drugs once the disease is controlled.
• Ifdosesofdiseasemodifyingorbiologicaldrugsarebeing
decreased, or the drugs are being stopped, arrange for
prompt review.
[The above three recommendations are based on high and
moderatequalityrandomisedcontrolledtrials,caseseries,and
the GDG’s opinion]
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PRACTICEManagement of symptoms: glucocorticoids
For people with recent onset or established
disease
• Offer short term glucocorticoid treatment for managing
flare-ups.[Basedonhighandmoderatequalityrandomised
controlled trials and on the GDG’s opinion]
In people with established disease
• Continue long term treatment with glucocorticoids only
after fully discussing with the individual the long term
complications of the treatment and after offering all other
treatment options (including biological drugs). [Based on
high and moderate quality randomised controlled trials
and the GDG’s opinion]
Monitoring rheumatoid arthritis
• RegularlymeasureCreactiveproteinandkeycomponents
of disease activity (using a composite score such as the
DAS28—a disease activity score that includes assessment
of 28 joints
3) to inform decision making about increasing
treatment to control disease or cautiously decreasing
treatment when disease is controlled. If the disease is of
recent onset and active, measure these variables monthly
until control reaches a level previously agreed with the
individual. [Based on high and moderate quality
randomised controlled trials, case series, and the GDG’s
opinion]
• Forpeoplewithsatisfactorilycontrolledestablisheddisease
offer review appointments at a suitable frequency and
location, ensuring that they know when and how to get
rapid access to specialist care, have access to additional
visits for disease flare-ups, and have ongoing drug
monitoring. [Based on high and moderate quality
randomised controlled trials and the GDG’s opinion]
• Offer annual review to:
-Assess disease activity, damage, and overall impact and
tomeasurefunctionalability(using,forexample,thehealth
assessment questionnaire
4)
-Check for comorbidities such as hypertension, ischaemic
heart disease, osteoporosis, and depression
-Assess symptoms that suggest complications, such as
vasculitis and disease of the cervical spine, lung, or eyes
-Organise appropriate cross referral within the
multidisciplinary team
-Assess the need for referral for surgery.
[Based on the GDG’s opinion]
Timing and referral for surgery
• Offerreferralforanearlyspecialistsurgicalopinionifany
of the following do not respond to optimal non-surgical
management:
-Persistent pain as a result of joint damage or other
identifiable damage to soft tissue
-Worsening joint function
-Progressive deformity
-Persistent localised synovitis.
[Based on the GDG’s opinion]
• For people with the following complications offer referral
foraspecialistsurgicalopinionbeforedamageordeformity
becomes irreversible:
-Imminent or actual tendon rupture
-Nervecompression(forexample,carpaltunnelsyndrome)
-Stress fracture.
[Based on the GDG’s opinion]
• Explainthatthemainexpectedbenefitsofsurgeryarepain
relief, improvement, or prevention of further deterioration
(of joint function and deformity). Cosmetic improvements
should not be the dominant concern. [Based on the GDG’s
opinion]
• Offer urgent combined medical and surgical management
tothosewithsuspectedorprovedsepticarthritis(especially
in a prosthetic joint). [Based on the GDG’s opinion]
• If any symptoms or signs suggesting cervical myelopathy
develop (for example, paraesthesiae, weakness,
unsteadiness,orextensorplantars)requesturgentmagnetic
resonance imaging, and refer for a specialist surgical
opinion. [Based on the GDG’s opinion]
• Do not let concerns about the long term durability of
prosthetic joints influence decisions to offer joint
replacements to younger people with rheumatoid arthritis.
[Based on the GDG’s opinion]
Diet and complementary therapies
• Inform people who wish to experiment with their diet that
no strong evidence exists that their arthritis will benefit.
However, encourage them to follow the principles of a
Mediterraneandiet(morebread,fruit,vegetables,andfish;
less meat; and replace butter and cheese with products
based on vegetable and plant oils). [Based on high quality
meta-analyses, high and moderate quality randomised
controlled trials, and the GDG’s opinion]
Inform those wishing to try complementary therapies that little
or no evidence exists for their long term efficacy and that
although some may provide short term symptomatic benefit,
complementary therapies should not replace conventional
treatment. Advise them that use of such therapies will not
preclude the offer of conventional care. [Based on
meta-analyses, randomised controlled trials, case series, and
the GDG’s opinion]
Overcoming barriers
Effective implementation of these recommendations depends
onearlyrecognitionofpersistentsynovitisinprimarycarewith
rapid referral to specialist care; aggressive use of disease
modifying antirheumatic drugs in active disease; close
monitoring of disease activity and intervention when control is
unsatisfactory; and multidisciplinary care for both recent onset
andestablishedrheumatoidarthritis.Generalpractitionersneed
to be taught how to recognise early synovitis and not to simply
treat the symptoms if the synovitis is persistent. Resources are
needed for specialist teams to see patients with recent onset
rheumatoid arthritis promptly and to follow them up regularly
with objective measures. However, this should not be at the
expense of treating those with established disease. Annual
reviewandongoingaccesstothemultidisciplinaryteamshould
be available to address the physical and psychosocial impact of
rheumatoid arthritis, ensure appropriate medication, and equip
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PRACTICEthepatientwiththeknowledge,skills,andresourcestominimise
the effects of the disease.
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PRACTICEFurther information on the guidance
A wealth of guidance is now available on the diagnosis, investigations, and treatment of rheumatoid arthritis. Treatment aims to control pain and
inflammation and to reduce joint damage, disability, and loss of function, thereby improving quality of life. This latest NICE guideline includes a
combination of pharmacological and non-pharmacological interventions but also highlights the importance of early diagnosis and intervention. It
draws on the most up to date evidence and pulls together areas covered in existing guidance
5-8 and in the NICE technology appraisals.
9-13 Its aim is
to improve the quality of life of patients and to reduce variation in practice, such as drug sequencing, choice and combination of disease modifying
antirheumatic drugs, and access to, and interventions provided by, the multidisciplinary team.
Methods
The guideline was developed using current NICE guideline methodology,
14 which involved systematic literature searches and critical appraisal and
summarising of evidence. A Guideline Development Group (GDG) discussed the evidence and formulated the clinical recommendations. The GDG
comprised people with rheumatoid arthritis as well as healthcare professionals representing a typical multidisciplinary team, both in primary and
secondary care, and invited experts when additional expertise was required. The supporting technical team included those with specific expertise
in literature search techniques, systematic evidence review, health economics, and project management.
The GDG accepted a clinical diagnosis of rheumatoid arthritis as being more important than the 1987 American Rheumatism Association’s classification
criteria for rheumatoid arthritis.
15 This is because an early persistent synovitis in which other disease has been ruled out needs to be treated as if it
is rheumatoid arthritis to try to prevent damage to joints. International committees are currently examining the diagnostic criteria for early rheumatoid
arthritis.
The GDG categorised rheumatoid arthritis into two categories: recent onset (disease duration of up to two years) and “established” (disease duration
of longer than two years). Within recent onset disease, categories of suspected persistent synovitis or suspected rheumatoid arthritis refer to patients
in whom a diagnosis is not yet clear but in whom referral to specialist care or further investigation is required.
The recommendations on NSAIDs replace the rheumatoid arthritis aspects only of NICE’s 2001 technology appraisal on cyclo-oxygenase-2 (COX
2) selective inhibitors.
11 All the recommendations (except the last one) in the latest guidance on rheumatoid arthritis are taken from NICE’s 2008
osteoarthritis guideline,
16 which updated the guidance on COX 2 selective inhibitors and NSAIDs. This was done because the GDG believed that
the results of the extensive cost effectiveness modelling for the osteoarthritis guideline were unlikely to differ for rheumatoid arthritis.
Health economic evidence was reviewed to evaluate whether guideline recommendations would be a cost effective use of healthcare resources.
The evidence comprised published economic analyses, which compare costs and benefits (in terms of quality adjusted life years) between two or
more interventions. Where health economic evidence was limited, the guideline process allowed the health economist from the GDG to develop a
new economic evaluation—for example, in evaluating the use of combinations of disease modifying antirheumatic drugs and steroids in patients with
early disease. The model is described in detail in the full NICE guideline.
2
The guideline was subject to a web based, external consultation from stakeholders. This drew 415 submitted comments, each of which was considered
by the GDG for its validity and usefulness, and where deemed appropriate the guideline was modified in the light of these.
NICE has produced four different versions of the guideline: a full version; a quick reference guide; a version known as the “NICE guideline” that
summarises the recommendations; and a version for patients and carers. All these versions are available from the NICE website (www.nice.org.uk/
CG79).
Additional recommendations: biological drugs
It was part of the remit of the GDG to re-evaluate the information outlined in NICE’s technical appraisal on anakinra
15 and incorporate updated
information in the new guideline, but after reviewing the evidence on anakinra, the GDG made no changes to the recommendations. The GDG also
had a remit to incorporate the information on other biological drugs outlined in the NICE technical appraisals.
9-13
• On the balance of its clinical benefits and cost effectiveness, anakinra is not recommended as a treatment for rheumatoid arthritis, except in
the context of a controlled, long term clinical study. If patients are already receiving anakinra, continue this until they and their consultant
consider it is appropriate to stop. [Based on a NICE technical appraisal[13]
• Do not offer the combination of tumour necrosis factor-α inhibitor therapy and anakinra. [Based on high and moderate quality meta-analyses
and randomised controlled trials]
Future research
The exercise of developing guidelines on managing rheumatoid arthritis drew attention to enormous gaps in the knowledge of the GDG. Several
areas not covered by the literature remain to be evaluated. Recognising early synovitis is not always straightforward, and clinical skills alone are not
always reliable. Thus the cost effectiveness of more objective tests such as magnetic resonance imaging, ultrasonography, and testing for anticyclic
citrullinated peptide antibodies needs to be examined in establishing the diagnosis and prognosis of small joint synovitis. Although the treatment of
early active disease has to be aggressive, the role of disease modifying antirheumatic drugs (and the effect of symptom duration on patient outcomes)
in the treatment of mild rheumatoid arthritis should be assessed. The cost effectiveness of early management with biological drugs (before the failure
of two conventional disease modifying antirheumatic drugs) should be assessed to determine if this could be a cost effective strategy in subgroups
of patients with rheumatoid arthritis. As more patients are exposed to biological therapies, research needs to determine the most appropriate treatment
strategy if a first tumour necrosis factor-α inhibitor fails.
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PRACTICE